The Gene Editing Tollbooth

Did you know that the first successful gene therapy was approved by the FDA just 33 years ago, back in 1990?

While most of us were arguing about whether compact discs would replace cassette tapes, some wild-eyed scientists were literally rewriting human DNA. Talk about thinking ahead.

Fast forward to today, and we’ve got Vertex Pharmaceuticals (VRTX) turning what seemed like pure fantasy into a $125 billion market cap reality.

Sometimes I wonder if those 1990 pioneers are sitting somewhere with a knowing smile, watching their “impossible” science create generational wealth.

Now, here’s the thing about Vertex that keeps me coming back like a moth to a particularly profitable flame.

This isn’t your garden-variety biotech gamble where you’re crossing your fingers and hoping some experimental drug doesn’t kill lab mice. No, sir, Vertex has built themselves what I like to call the “Warren Buffett Special” of pharmaceutical franchises with their cystic fibrosis treatments.

We’re talking about $2.77 billion in quarterly revenue as of Q1 2025, up 3% year-over-year, which might not sound like fireworks until you realize this cash machine has patent protection through 2037.

That’s the kind of predictable income stream that makes retirement planners weep with joy.

The company is guiding toward $11.85 to $12 billion for full-year 2025 revenue, representing about 8% growth at the midpoint.

Sure, 8% won’t get you invited to any Silicon Valley dinner parties, but when you’re dealing with life-or-death medications for a clearly defined patient population, steady and reliable beats flashy and unpredictable every single time.

It’s like owning a toll road, except instead of collecting quarters from commuters, you’re collecting billions from people who literally can’t live without your product.

But here’s where things get deliciously interesting, and why I think most investors are missing the real story.

While everyone’s busy calculating CF revenue growth rates, Vertex has been quietly assembling what could be the medical equivalent of the Manhattan Project. Their gene editing therapy, called Casgev, just posted some absolutely bonkers long-term data that honestly makes me question whether we’re witnessing the dawn of a new era in human health.

Get this: 95.6% of sickle cell disease patients were completely free from painful crises for at least 12 months after treatment.

Now, if you’ve never experienced or watched someone go through a sickle cell crisis, imagine the worst pain you’ve ever felt, multiply it by 10, and then imagine living with the constant fear that it could happen again any day.

These folks typically end up in emergency rooms multiple times per year, racking up medical bills faster than a teenager with a new credit card. Casgevy essentially takes that nightmare and erases it…potentially forever.

Here’s the part that makes my inner accountant both excited and slightly nauseous: the treatment costs over $2 million per patient. That’s right, two million with six zeros.

It sounds absolutely insane until you realize that the average sickle cell patient with recurrent crises costs the healthcare system about $67,000 annually.

Simple math tells us that’s roughly 30 years of medical expenses paid upfront for what appears to be a permanent cure.

Vertex expects about $85 million in gene therapy revenue for 2025, which sounds modest until you consider they’re essentially building the assembly line for the future of medicine.

Their CEO recently mentioned having about 90 patients who’ve started cell collection, with potentially 270 more in the pipeline. At $2 million a pop, even modest adoption rates start looking like serious money.

What really gets my blood pumping, though, is the pipeline behind the pipeline.

Their Type 1 diabetes therapy, zimislecel, showed that 10 out of 12 patients ditched their daily insulin shots entirely by month 12, with an average 92% reduction in insulin requirements.

Consider that there are roughly 1.25 million Americans with Type 1 diabetes, and suddenly, we’re not talking about niche markets anymore. We’re talking about potentially obsoleting an entire category of chronic disease management.

The company’s sitting pretty financially too, with strong cash reserves, minimal debt, and the kind of free cash flow that funds continued moonshots.

Their recent $4.9 billion acquisition of Alpine Immune Sciences shows they’re not content to rest on their CF laurels but are actively hunting for the next breakthrough.

But the real question isn’t whether Vertex can keep printing money from their existing franchise. It’s whether they can pull off the ultimate corporate transformation from a one-trick pony into a gene therapy juggernaut.

Given their track record of turning Nobel Prize-winning science into blockbuster businesses, combined with their financial firepower and expanding pipeline, I’d say the odds are pretty favorable. I suggest you buy the dip.